Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aura Biosciences (AURA) Shares Outstanding (Diluted Average) (2021 - 2026)

Aura Biosciences filings provide 6 years of Shares Outstanding (Diluted Average) readings, the most recent being $67.4 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 34.56% to $67.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $67.4 million through Mar 2026, up 34.56% year-over-year, with the annual reading at $60.3 million for FY2025, 21.52% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $67.4 million in Q1 2026 for Aura Biosciences, up from $60.3 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $67.4 million in Q1 2026 and bottomed at $29.2 million in Q1 2022.
  • Average Shares Outstanding (Diluted Average) over 5 years is $45.1 million, with a median of $49.5 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding (Diluted Average) surged 6582.3% in 2022 before it grew 1.36% in 2025.
  • Aura Biosciences' Shares Outstanding (Diluted Average) stood at $29.9 million in 2022, then skyrocketed by 32.34% to $39.6 million in 2023, then increased by 25.32% to $49.7 million in 2024, then rose by 21.52% to $60.3 million in 2025, then rose by 11.78% to $67.4 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Shares Outstanding (Diluted Average) are $67.4 million (Q1 2026), $60.3 million (Q4 2025), and $65.9 million (Q3 2025).